SEC Form 4 · accession 0000899243-18-030438
Eidos Therapeutics, Inc. · EIDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Lis
Director
Period of report
Dec 4, 2018
Accepted (ET)
Dec 7, 2018 · 8:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001731831
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $13.67 | Dec 4, 2018 | A | 43,056 | A | — | Dec 4, 2028 | Common Stock | 43,056 | 43,056 | D |
Explanation of responses
- F1The option grant was approved by the Issuer's board of directors on December 4, 2018, and is subject to cancellation if the Issuer's shareholders do not approve an increase to the share reserve of the stock option plan under which the option was granted by December 4, 2019.
- F2The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 43,056 stock options (the "Grant") on December 4, 2018. The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following December 4, 2018 subject to the Reporting Person's continued service to the Issuer through each vesting date.